Ornithine Transcarbamylase Deficiency Treatment Market

Ornithine transcarbamylase deficiency treatment is fastest growing segment fueling the growth of ornithine transcarbamylase

by

The global ornithine transcarbamylase deficiency treatment market is estimated to be valued at US$ 810.4 Mn in 2023 and is expected to exhibit a CAGR of 4.2% over the forecast period from 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Ornithine transcarbamylase deficiency is a rare genetic condition that causes excess ammonia in the blood. It affects the ability of the liver to break down protein. The deficiency treatment market comprises medicines like carglumic acid and glycerol phenylbutyrate to reduce toxic ammonia levels in the body.

Market key trends:
Rising cases of hyperammonemia disorders globally is expected to drive the ornithine transcarbamylase deficiency treatment market growth over the forecast period. According to a study published in the American Journal of Medical Genetics in 2020, the prevalence of urea cycle disorders including ornithine transcarbamylase deficiency is estimated to range from 1 in 35,000 to 1 in 833,333 live births worldwide. Growing awareness about rare disease treatment options is also anticipated to boost the market growth during the forecast period.
Segment Analysis
The global ornithine transcarbamylase deficiency treatment market is segmented into treatment type and distribution channel. Based on treatment type, the market is classified into dietary supplements, nitrogen scavengers, and nitrogen binders. The nitrogen scavengers segment dominates the market due to its ability to remove ammonia from the blood stream in patients with OTC deficiency.

Key Takeaways
The global Ornithine Transcarbamylase Deficiency Treatment Market Share is expected to witness high growth, exhibiting a CAGR of 4.2% over the forecast period, due to increasing prevalence of inherited urea cycle disorders.

Regional analysis
North America dominates the ornithine transcarbamylase deficiency treatment market owing to the increasing incidence of UCDs and growing research activities on OTC deficiency treatment in the region.

Key players
Key players operating in the ornithine transcarbamylase deficiency treatment market are Horizon Therapeutics Plc, Bausch Health Companies Inc., Danone, Nestlé, Ultragenyx Pharmaceutical., Arcturus Therapeutics, Inc., Abbott., Swedish Orphan Biovitrum AB, Acer Therapeutics Inc., Assertio Holdings, Inc., iECURE, and Translate Bio, Inc.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it